R
RECURSION PHARMACEUTICALS INC
NASDAQ: RXRX (Recursion Pharmaceuticals, Inc.)
Kemas kini terakhir: 18 jam lalu4.71
-0.21 (-4.27%)
| Penutupan Terdahulu | 4.92 |
| Buka | 4.87 |
| Jumlah Dagangan | 16,558,934 |
| Purata Dagangan (3B) | 42,884,679 |
| Modal Pasaran | 2,455,147,520 |
| Harga / Jualan (P/S) | 43.05 |
| Harga / Buku (P/B) | 2.32 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Operasi (TTM) | -1,297.85% |
| EPS Cair (TTM) | -1.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 9.95% |
| Nisbah Semasa (MRQ) | 4.11 |
| Aliran Tunai Operasi (OCF TTM) | -388.83 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -204.88 M |
| Pulangan Atas Aset (ROA TTM) | -38.51% |
| Pulangan Atas Ekuiti (ROE TTM) | -86.10% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Recursion Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
-0.5
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -4.0 |
| Purata | -0.50 |
|
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.78% |
| % Dimiliki oleh Institusi | 69.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ark Investment Management Llc | 30 Sep 2025 | 33,545,499 |
| Softbank Group Corp. | 30 Sep 2025 | 14,667,491 |
| Kinnevik Ab (Publ) | 30 Sep 2025 | 13,434,171 |
| Mubadala Investment Co Pjsc | 30 Sep 2025 | 12,985,927 |
| Mic Capital Management Uk Llp | 30 Sep 2025 | 9,644,032 |
| Sumitomo Mitsui Trust Group, Inc. | 30 Sep 2025 | 7,465,858 |
| Amova Asset Management Americas, Inc. | 30 Sep 2025 | 7,465,858 |
| Data Collective Iv Gp, Llc | 30 Sep 2025 | 5,941,120 |
| Julat 52 Minggu | ||
| Median | 8.00 (69.85%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 11 Sep 2025 | 8.00 (69.85%) | Beli | 4.85 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| TAYLOR BEN R | - | 4.37 | -2,271 | -9,924 |
| Jumlah Keseluruhan Kuantiti Bersih | -2,271 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -9,924 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 4.37 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TAYLOR BEN R | Pegawai | 25 Nov 2025 | Dibuang (-) | 2,271 | 4.37 | 9,924 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 Dec 2025 | Pengumuman | Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 |
| 05 Nov 2025 | Pengumuman | Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 05 Nov 2025 | Pengumuman | Recursion Announces CEO Transition Plan to Drive Next Phase of Growth |
| 04 Nov 2025 | Pengumuman | Recursion to Participate in Upcoming Investor Conferences |
| 28 Oct 2025 | Pengumuman | Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |